Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals

Jorge F A Model*, Débora S Rocha, Alessa da C Fagundes, Anapaula S Vinagre

Department of Physiology, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil

ARTICLE INFO

Keywords:
GLP-1
Cats
Diabetes mellitus
Obesity
Incretin

ABSTRACT

Analouges of glucagon like peptide-1 (GLP-1) and other drugs that increase this peptide half-life are used worldwide in human medicine to treat type 2 diabetes mellitus (DM) and obesity. These molecules can increase insulin release and satiety, interesting effects that could also be useful in the treatment of domestic animals pathologies, however their use in veterinary medicine are still limited. Considering the increasing incidence of DM and obesity in cats and dogs, the aim of this review is to summarize the available information about the physiological and pharmacological actions of GLP-1 in domestic animals and discuss about its potential applications in veterinary medicine. In diabetic dogs, the use of drugs based on GLP-1 actions reduced blood glucose and increased glucose uptake, while in diabetic cats they reduced glycemic variability and exogenous insulin administration. Thus, available evidence indicates that GLP-1 based drugs could become alternatives to DM treatment in domestic animals. Nevertheless, current data do not provide enough elements to recommend these drugs widespread clinical use.

1. Introduction

Glucagon like peptide-1 (GLP-1) is a peptide hormone synthetized by intestinal "L" cells, which are located mainly in the most distal intestinal regions, such as the ileum and colon. This peptide is also produced in the ileum (Deacon, 2018; Nauck & Parkes, 2011). GLP-1 originated in intestinal "L" cells, which are located mainly in the most distal intestinal regions, such as the ileum and colon. This peptide is also produced in the ileum (Deacon, 2018; Nauck & Parkes, 2011). GLP-1 has an extremely short half-life due to rapid degradation by dipeptidylpeptidase 4 (DPP4), also known as CD26, a serine peptidase produced in the vascular endothelium (Deacon, 2018; Nauck & Meier, 2018). Recent data indicates that GLP-1 originated in a cells also has a central role in the stimulation of insulin release by β cells, in an intra-islet paracrine action (Chambers et al., 2017; Smith et al., 2014).

Regardless of its origin, islet β cells or enteroendocrine L cells, when GLP1 reaches the β cells and binds to its receptor (GLP-1R), a series of events that culminate in insulin release amplification are triggered (Fig. 2) (Müller et al., 2019). When GLP-1R, a G protein-coupled receptor, is activated, adenylate cyclase is activated resulting in ATP conversion to cAMP (Meloni, DeYoung, Lowe & Parkes, 2013). To stimulate the insulin release, this second messenger activates mainly two pathways: protein kinase A (PKA) and the exchange protein directly activated by cAMP (Epac) (Kang, Leech, Chepurny, Coetzee & Parkes, 2013). PKA phosphorylates the KATP channels, sensitizing them to ATP and facilitating their closure, thus promoting cell depolarization and opening the VDCC, leading to an increase in glucose administration, despite similar blood glucose levels. (Baggio & Drucker, 2007; Nauck & Meier, 2018). GLP1 has an extremely short half-life due to rapid degradation by dipeptidylpeptidase 4 (DPP4), also known as CD26, a serine peptidase produced in the vascular endothelium (Deacon, 2018; Nauck & Meier, 2005). Recent data indicates that GLP-1 originated in α cells also has a central role in the stimulation of insulin release by β cells, in an intra-islet paracrine action (Chambers et al., 2017; Smith et al., 2014).

After its release by L cells, GLP-1 enters the portal circulation and reach the pancreatic islets, where it exerts the so-called incretin effect (Baggio & Drucker, 2007; Nauck & Meier, 2018). The incretin effect is described as a higher insulin release resulting from oral than intravenous administration, despite similar blood glucose levels. (Baggio & Drucker, 2007; Nauck & Meier, 2018). GLP1 has an extremely short half-life due to rapid degradation by dipeptidylpeptidase 4 (DPP4), also known as CD26, a serine peptidase produced in the vascular endothelium (Deacon, 2018; Nauck & Meier, 2005).

* Corresponding author at: Programa de Pós-Graduação em Ciências Biológicas: Fisiologia, Departamento de Fisiologia, Laboratório de Metabolismo e Endocrinologia Comparada (LaMEC), Universidade Federal do Rio Grande do Sul (UFRGS), Instituto de Ciências Básicas da Saúde (ICBS), Rua Sarmento Leite, 500, Porto Alegre, RS, CEP 90050-170, Brazil
E-mail address: jorgefamodel@gmail.com (J.F.A. Model).

https://doi.org/10.1016/j.vas.2022.100245
Received 3 December 2021; Received in revised form 25 February 2022; Accepted 14 March 2022
Available online 23 March 2022
2451-943X/© 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
intracellular Ca$^{++}$ (Bünemann, Gerhardstein, Gao & Hosey, 1999; MacDonald et al., 2003; Rowlands et al., 2018). PKA also inhibits voltage-dependent K$^+$ channels, delaying repolarization of β cells (MacDonald et al., 2003). In addition to this rapid stimulation of insulin release, PKA also interacts with pancreatic and duodenal homeobox 1 (Pdx-1), leading to stimulation of the proinsulin gene transcription, which increases the stability of its mRNA, thus promoting insulin synthesis (D. J. Drucker, Philippe, Mojsov, Chick & Habener, 1987; Müller et al., 2019; Wang et al., 1995). Epac also acts sensitizing the K$_{ATP}$ channels, but its main function is to facilitate the opening of ryanodine receptor calcium release channels (RYR) on the endoplasmic reticulum, amplifying the intracellular Ca$^{++}$ increase (Holz, 2004; Kang et al., 2008). It is important to note that the actions of PKA and Epac potentiates and enhances β cells response to the increase in circulating glucose, but without concomitant increase in intracellular ATP, therefore, GLP-1 signal is a weak insulin release promoter (Müller et al., 2019).

Besides its acute effects, GLP-1 also has long-term effects on β cells, that are mainly related to apoptosis inhibition and cellular multiplication (J. Buteau et al., 2004; Jean Buteau, Foisy, Joly & Prentki, 2003; Kapodistria, Tsilibary, Kotsopoulou, Moustardas & Kitsiou, 2018; Shimoda et al., 2011; Tsunekawa et al., 2007). However, studies with diabetic human patients have not shown an increase in β cells proliferation (Smits et al., 2017). Pancreatic islets α and δ cells also express GLP-1R, therefore GLP1 binding can also inhibits glucagon and stimulates somatostatin release (de Heer, Rasmussen, Coy & Holst, 2008; Ørskov, Holst & Nielsen, 1988; Richards et al., 2014).

Much of the interest in GLP-1 is due to its action on pancreatic islets, however, it was described in rodents and humans that several other tissues express GLP-1R (Müller et al., 2019; Rowlands et al., 2018). GLP-1R has already been identified in the stomach, skeletal muscle, smooth muscle, atrial cardiac muscle, kidneys, lungs, adipose tissue and in several areas of the central nervous system (CNS) (Bullock, Heller & Habener, 1996; Challa et al., 2012; Delgado et al., 1995; Richards et al., 2014). Some authors have already reported the presence of GLP-1R in the liver, however, the most recent results indicate that these findings are mainly due to findings with non-specific antibodies, and that hepatocytes of mice, humans and monkeys (Macaca mulatta and Macaca fascicularis) do not express GLP-1R (Drucker, 2018; Knudsen & Lau, 2019; Pyke et al., 2014). To our best knowledge, GLP-1R presence in dogs and cats’ liver was not evaluated yet.

GLP-1 has several important extra pancreatic functions, and most of them depend on actions in the CNS. It increases satiety and thermogenesis, inhibits blood pressure rising, gastric emptying and water

---

**Fig. 1.** Schematic illustration of GLP-1 release after glucose uptake in enteroendocrine L cells. SGLT: sodium-glucose linked transporter. K$_{ATP}$: ATP-sensitive K$^+$ channels. VDCC: voltage dependent calcium channels.
intake, is involved in the reward pathway and in the hypothalamic adrenal pituitary (HPA) axis (Beiroa et al., 2014; Hayes, Skibicka & Grill, 2008; Herman, 2018; Imeryüz et al., 1997; Kooijman et al., 2015; Krieger et al., 2016; Pacheco et al., 2011; Rüttimann, Arnold, Hillebrand, Geary & Langhans, 2009; Sirohi, Schurdak, Seeley, Benoit & Davis, 2016; Tang-Christensen et al., 1996; Wettergren, Wojdemann, Meisner, Stadil & Holst, 1997). GLP-1 also acts on the cardiovascular system, either directly binding to GLP-1R in cardiomyocytes and vascular smooth muscle cells, and indirectly, by its CNS actions (Baggio et al., 2017; Ban et al., 2008). Considering the increasing incidence of diabetes mellitus (DM) and obesity in cats and dogs, the aim of this review is to summarize the available information about the physiological and pharmacological actions of GLP-1 in domestic animals and discuss about its potential applications in veterinary medicine.

2. Material and methods

To find the studies that evaluated the action of drugs based on GLP-1 in dogs and cats, we used the platforms PubMed/NCBI, Scopus, Web of Science and Google Scholar to search for the terms “dog and GLP-1“, “canine and GLP-1“, “cat and GLP-1“, “feline and GLP-1“, “pet and GLP-1“ in addition to their plurals. We performed the same searches again but replacing the term “GLP-1“ with “glucagon like peptide-1“ and then with the term “incretin“. These searches were carried out between May and June 2021, no restrictions on publication date were imposed. Only papers in English were found and considered. All authors performed searches independently. Afterwards, all papers were gathered (disregarding replicates) and two individuals independently evaluated which ones should be included. As the inclusion criterion was any article that addressed the proposed topic, there were no discrepancies in the results obtained by the reviewers. From 30 papers found, all that addressed these topics were included in the discussion below, with the

Fig. 2. Schematic illustration of the intracellular signaling cascade by which GLP-1 stimulates insulin release in β cells. AC: adenylate cyclase. Epac: exchange protein directly activated by cAMP. PKA: protein kinase A. K_{ATP}: ATP-sensitive K^+ channels. VDCC: voltage dependent calcium channels. K_v: voltage-dependent K^+ channels. PDX-1: pancreatic and duodenal homebox 1. RYR: ryanodine receptor calcium release channels.
exception of one (Padrut, Lutz, Reusch & Zini, 2015). This study was excluded because the authors did not perform a statistical analysis of the data.

3. Physiological actions of GLP-1 in dogs and cats

Most of the studies cited so far, which allow us to understand GLP-1 physiological importance and its pharmacological potential, have been carried out using rats, mice, human volunteers and cell lines of these three species. However, some studies with dogs and cats demonstrate GLP-1 species-specific characteristics. In dogs, GLP-1 is also synthetized and released by intestinal L cells, especially in the jejunum (Damholt, Kofod & Buchan, 1999). However, the classic form of GLP-1 release, shown in Fig. 1, does not seem to occur in dogs, with at least part of GLP-1 release being stimulated by GIPs (from K cells) paracrine action (Damholt et al., 1999; Damholt, Buchan & Kofod, 1998; Sugiyama et al., 1994). Also, while glucose is the main inducer of GLP-1 release in humans and rodents, in dogs high fat diets stimulate GLP-1 release, while carbohydrate-rich diets do not have the same effect (Fig. 3) (Lubbs et al., 2010; Schauf et al., 2018; Van Citters et al., 2002).

As well as in other species, GLP-1 stimulates insulin release in dogs (Ohneda et al., 1991). GLP-1 administration directly into the pancreatic artery stimulates insulin and inhibits glucagon release in dogs, however, when GLP-1 is administered in venous circulation, it had no effect on pancreatic hormones. (Elahi et al., 2014; Ionut et al., 2006; V. Ionut, Hucking, Liberty & Bergman, 2005; Johnson et al., 2007, 2008; Ohneda et al., 1991). The administration of DPP4 inhibitors in dogs leads to an increase in GLP-1, but it does not alter insulinemia. (Deacon, Wamberg, Bie, Hughes & Holst, 2002; Edgerton et al., 2009). Even in experiments without changes in pancreatic hormones, GLP-1 is able to stimulate glucose uptake and hepatic glycogen synthesis (Dardevet et al., 2005; Elahi et al., 2014; Johnson et al., 2007, 2008). In animals with diabetes mellitus (DM), GLP-1 does not alter blood glucose, and in pancreatic-teratomized dogs it has no effects when administered alone, but improves glucose utilization and the antilipolytic action promoted by exogenous insulin. (Freyse et al., 1999; Sandhu et al., 1999). These findings suggest that GLP-1 may have an indirect action on peripheral tissues, increasing insulin sensitivity.

The incretin effect is also observed in cats (Gilor et al., 2011b; Nishii et al., 2014). Different GLP-1R agonists increase plasma insulin concentration in cats as well as in rodents and humans (Gilor et al., 2011a; Hall et al., 2015; Rudinsky et al., 2015). There are evidences that GLP-1 degradation by DPP4 in cats is also similar to other species (Mori et al., 2016; Nishii et al., 2014). As in dogs, glucose also does not seem to be the main stimulus for the release of GLP-1 in cats. After amino acids rich meals, there is a higher increase in plasmatic GLP-1 than after meals rich in carbohydrates or lipids, with no difference between the last two. The diets used in these studies were caloric and volume equivalent (Gilor et al., 2011b; McCool, Rudinsky, Parker, Herbert & Gilor, 2018). The number of meals can also affect plasma GLP-1 concentration, with cats that received 1 meal per day having higher values than those that received 4 meals (Camara et al., 2020). However, dietary caloric changes over 16 weeks were not able to alter the plasmatic GLP-1 (McCool et al., 2018).

4. GLP-1 pharmacology

The known physiological actions of GLP-1 indicate a great potential for its pharmacological use in obesity and DM treatment. However, some factors turn its use unfeasible. The main issues about GLP-1 use as a treatment are its short half-life (around 1–2 min) and the fact that its administration in high doses causes gastrointestinal complications such as nausea, vomiting and diarrhea (Baggio & Drucker, 2002; Nauck & Meier, 2005). To overcome these limitations, two general types of drugs that use the incretin mechanism of action have been developed, the synthetic GLP1 agonists (GLP-1As) and the DPP4 inhibitors (DPP4-is) (Nauck & Meier, 2005). Although these drugs have been developed for use in humans, both types have already been tested in dogs and cats (Gilor, Rudinsky & Hall, 2016; Ionut et al., 2016; Kim et al., 2016). One of the main advantages of using DPP4-is or GLP-1As is that they have...
few side effects, being highly safe (Aziz et al., 2020; Scheen, 2018).

4.1. GLP-1 pharmacology in cats

The similarity between human type 2 DM and feline DM pathogenesis makes natural that drugs successfully used in humans treatment be evaluated for their use in cats (Gilor, Niessen, Furrow & DiBartola, 2016). Although the same reasoning is valid for drugs used to treat obesity in humans, there are very few studies evaluating drugs based on GLP-1 in obese cats (Table 1).

Despite the similarities in the pathogenesis of obesity, the relationship between this disease and incretins in felines seems to be different from that observed in humans and rodents. In these species obesity leads to an increase in GIP and decrease in GLP-1 (Chia & Egan, 2020). Diabetic cats were shown to have lower insulin levels than healthy and obese animals, but both GIP and GLP-1 were increased (McMillan, Zapata, Chelikani, Snead & Cosford, 2016). Unlike in humans, there was no difference in GIP and GLP-1 between healthy and obese felines. Even insulin was not altered between obese and healthy cats, something that has already been reported in other studies. (Appleton, Rand & Sunvold, 2001; Hoenig et al., 2013; McMillan et al., 2016). We found no studies evaluating treatment of obese cats with DPP4-is and just one in which GLP-1A was used for treatment in obese cats. In this study, the animals received the GLP-1A exenatide (0.5 – 1 µg·kg⁻¹·BID) for 12 weeks, but the treatment did not result in differences in total weight, percentage of body fat, glycemia, leptin, adiponectin, glucagon and in glucose and insulin tolerance tests (GTT and ITT) (Hoelmkjær et al., 2016).

In addition to the lack of studies about DPP4-is in obese cats, we did not find any reports in diabetic felines, only healthy animals. A single application of the DPP4i NVP-DPP728 (0.5 – 2.5 mg·kg⁻¹) increased insulin and reduced glucagon release in a GTT. The authors attribute these results to the increase in GLP-1, although it was not directly measured (Furrer, Kaufmann, Tschuo, Reusch & Lutz, 2010). In another study with a DPP4i, sitagliptin (25 – 50 mg·kg⁻¹) was administered along with oral glucose or with standard food. GLP-1 increased in cats that received sitagliptin regardless of diet. On the other hand, blood glucose only increased in cats who received oral glucose. Insulinemia increased in animals that received standard food regardless of whether or not sitagliptin was administered, but those that received glucose only showed an increase in insulin concentrations when the DPP4i was also administered (Nishii et al., 2014).

Mori et al. (2016) evaluated sitagliptin administration (4.2 mg) alone, acarbose (disaccharide digestion inhibitor) alone, or both together in healthy cats. After two weeks of treatment, the cats were fed a maltose-rich meal. Blood glucose was not altered in any of the groups, insulin decreased in all treatments, GLP-1 increased in groups with sitagliptin (alone or with acarbose) while GIP decreased in these same groups. Regardless of the type of food or another drug concomitant administration, the DPP4i evaluated was able to increase GLP-1 in the studied animals. However, both glycaemia and insulinemia did not show such a clear response to sitagliptin treatment, leading the authors themselves to raise doubts about this drug value in DM cats treatment

Table 1

GLP-1-based drug studies in cats.

| Breed | Age (years) | sex | Castration | "n" per group | Condition | Drug | Brant / Manufacturer | Dosage | Treatment Duration | Complications | Ref |
|-------|-------------|-----|------------|--------------|-----------|------|----------------------|--------|--------------------|--------------|-----|
| NI    | 8.0 ± 1.1   | F/  | All        | 2 - 3        | healthy   | sitagliptin | Januvia/ Banyu Pharmaceutical | 25 – 50 mg·kg⁻¹ | acute              | NO           | (Nishii et al., 2014) |
| NI    | 1 to 4      | F/  | All        | 5           | healthy   | sitagliptin | Januvia/ Merck & Co. Inc | 4.2 mg * | 1 week             | diarrhea     | (Mori et al., 2016) |
| DSH   | 1.3 to 2    | M   | All        | 6           | healthy   | NVP- DPP728 exenatide | Byetta/Eli Lilly | 0.5 - 1 mol·kg⁻¹ | acute              | NO           | (Furrer et al., 2010) |
| DSH, BSH, Burmilla and mixed breeds | above 3 | F/  | All        | 6           | obese     | exenatide | Byetta/Eli Lilly | 0.5 - 1 µg·kg⁻¹ | 12 weeks | vomiting, diarrhea and hypoglycemia | (Hoelmkjær et al., 2016) |
| NI    | 2 to 8      | F/  | M          | 6           | healthy   | exenatide | Byetta/Eli Lilly | 0.1 – 0.24 - 1 µg·kg⁻¹ | acute              | NO           | (Seyfert et al., 2012) |
| purpose-bred | 4.5 (3.1 – 4.8) | F/  | M          | 9           | healthy   | exenatide | Byetta/Amylin Pharmaceuticals | 1.04 ± 0.18 µg·kg⁻¹ | acute              | NO           | (Gilor et al., 2011a) |
| purpose-bred | 3          | M   | All        | 6           | healthy   | exenatide | Bydureon/Amylin Pharmaceuticals | 0.13 mg·kg⁻¹ | 21 days | NO              | (Rudinsky et al., 2015) |
| purpose-bred | 3          | M   | All        | 8           | healthy   | exenatide | Victora/ Novo Nordisk | 0.112 ± 0.019 mg·kg⁻¹ | 8 days | vomiting, diarrhea and anorexia | (Iball et al., 2015) |
| DSH   | 1 to 4      | M   | NI         | 6           | healthy   | exenatide | synthesized by the research group | 1.2 – 4.6 µmol | 10 weeks | vomiting and diarrhea | (Schneider et al., 2020) |
| DSH, DLH** | 9.4 ± 3.7  | F/  | 14 – 15    | 15          | DM        | exenatide | Bydureon/Amylin Pharmaceuticals | 200 µg·kg⁻¹ | 16 weeks | vomiting and diarrhea | (Riederer et al., 2020) |
| DSH, DMH and Siamese cross | 12 (6 – 15) | F/  | All        | 8           | DM        | exenatide | Byetta/Eli Lilly | 1 µg·kg⁻¹ | 6 weeks | anorexia and hypoglycemia | (Scuderi et al., 2018) |
| DSH, DLH, Maine Coons, NFC, Exotic | 9.3 (4.3 – 14) | F/  | 14 – 15    | 15          | DM        | exenatide | Bydureon/Amylin Pharmaceuticals | 200 µg·kg⁻¹ | 16 weeks | NI              | (Kramer et al., 2020) |

NO: not observed. NI: not informed. DM: diabetes mellitus. DSH: Domestic shorthair. BSH: British shorthair. DLH: Domestic longhair. DMH: Domestic mediumhair. NFC: Norwegian forest cat. ER: extended release.

* the authors reported only the total administered.

** 4 cats were identified as "purebred" by the authors.
Exenatide acute actions were evaluated in two different studies with term effects. In DM cats it was tested only together with insulin therapy. In healthy individuals, GLP-1A has been evaluated for its short and long- (Nishii et al., 2014).

Longer-term treatments were performed with GLP-1As, daily liraglutide applications or with a single administration of extended release exenatide. In an 8-day treatment with daily applications of liraglutide (0.6 mg (0.112 ± 0.019) mg.kg^-1) two hyperglycemic clamps were evaluated, one performed before and the other after treatment. As occurred in the acute studies, the GLP-1A did not lead to differences in the infused glucose concentration needed to maintain glycemia, however insulin release increased while glucagon release decreased after the treatment. Another interesting result, but which should be evaluated with caution, was that the animals lost weight after 8 days receiving liraglutide. Although this is a promising result, it is necessary to emphasize that 8 of the 9 cats used in the study had at least one episode of vomiting or diarrhea, which may have influenced weight loss (Hall et al., 2015).

Different types of long acting exenatide have been tested for their efficacy and pharmacological characteristics in cats. Two hyperglycemic clamps, performed 7 days before and 21 days after the application of a single extended-release exenatide dose (0.13 mg.kg^-1), were compared. Initial blood glucose was lower after treatment, while initial insulin and glucagon concentrations did not change. Glucose administered to maintain hyperglycemia was higher after exenatide, while insulin release increased and glucagon release decreased (Rudinsky et al., 2015). A recently developed exenatide formulation that allows for monthly applications had similar pharmacological and pharmacodynamic characteristics to traditional exenatide (1.2–4.6 µmol) and was able to stimulate insulin release in an ivGTT, although it did not change glucose concentrations (Schneider et al., 2020).

In diabetic cats, no GLP-1A has been studied as a single treatment, but it has been tested with insulin therapy, presenting inconsistent results. Diabetic cats were treated with insulin glargine plus exenatide (1 µg.kg^-1 BID) or saline for 6 weeks. There was no difference in blood glucose, hematomalous and biochemical parameters between treatments, however animals that received exenatide lost more weight than those who received saline and needed lower insulin doses to maintain blood glucose (Scuderi et al., 2018). DM cats newly diagnosed were treated with insulin glargine alone or together with long-acting exenatide (weekly application of 200 µg.kg^-1). After 16 weeks no significant difference was observed in plasma biochemistry (including glucose and glycated fructosamine) and in the insulin dose required to maintain blood glucose. The only difference observed was an increased weight of animals that received just insulin, while it did not occur in those treated with insulin and exenatide (Riederer et al., 2016). In a similar experiment Krämer et al. (2020) also compared newly diagnosed diabetic cats that received insulin glargine alone or with long-acting exenatide (weekly application of 200 µg.kg^-1 for 16 weeks). Again, there were no differences in glycemia, however animals that received exenatide had less variability in this parameter and reached normoglycemia earlier, after 6 weeks, while the placebo group reached normoglycemia after 16 weeks. Because in all three studies glycemia was controlled by insulin treatment, it is not surprising that this parameter was not different between insulin and insulin plus exenatide groups. However, unlike what was observed with DPP4i, the use of GLP-1As showed improvements in animal treatment by reducing the required insulin dose and glycemic variability. Even though a larger body of evidence is needed to reach conclusions about the effectiveness of GLP-1A treatments in cats, the results obtained so far demonstrate that these drugs may be used, at least as adjuvants, in the DM treatment.

4.2. GLP-1 pharmacology in dogs

Regarding the modulation of endogenous GLP-1 and DM, no articles were found related to DPP4i use in diabetic dogs (Table 2). This absence is expected considering the expressive loss of pancreatic β cells in canine DM (Deacon et al., 2002; Edgerton et al., 2009; Ionut et al., 2006). However, considering that GLP-1 effects are not necessarily restricted to the pancreas, it could be evaluated in DM dogs (Edgerton et al., 2009; Ionut et al., 2006; Johnson et al., 2007). In healthy dogs, DPP4i administration showed contradictory results (Table 2). The DPP4i vil dagliripin increased hepatic glucose uptake regardless of changes in circulating insulin or glucagon levels (Edgerton et al., 2009). Consistently, semiglalitin improved the oral GTT (oGTT) profile compared to control, increased GLP-1, and decreased glucagon after glucose load (Kim et al., 2016). However, sitagliptin did not improve the oGTT curve (Hitomi Oda et al., 2014). Although the three studies used equal drug doses (1 mg.kg^-1) and similar sample sizes (4–6), variations in results may be due to differences in dogs breeds, sexes, and treatment duration.

Early studies with GLP-1 or its analogues in diabetic dogs also showed conflicting results. In depancreatized dogs, glucose utilization increased, while circulating free fatty acids and glycerol reduced when GLP-1 (7–36) amide (1.5 pmol.kg^-1.min^-1) was administered along with insulin Sandbu et al., 1999). In the same year, Fryse et al. (1999) performed a normoglycemic clamp in DM dogs with combined therapy of insulin and GLP-1(7–36) amide (10 pmol.kg^-1.min^-1). The administration of GLP-1 did not change insulin, glucose, and glucagon infusions rate. There were also no differences in metabolic glucose clearance, alanine turnover, urea synthesis and glucose formation by gluconeogenesis using alanine as precursor. This investigation line was resumed only in 2013. In healthy and DM dogs, liraglutide treatment (15 µg.kg^-1) reduced the area under the curve in an oGTT. Also, in diabetic dogs the circulating glucose decreased by 66.5% with liraglutide compared to dogs treated with insulin alone, revealing its potential use in DM. The authors correlate the suppression of glucagon secretion with the observed effect (Oda et al., 2013).

Few studies with GLP-1, GLP-1A or DPP4i treatment have been conducted in DM dogs, but the outcomes in healthy animals point to a potential utilization of these drugs. Lisixenatide (1.5 µg.kg^-1), a GLP-1A, decreased glucose and insulin areas under the curves (Moore, Werner, Smith, Farmer & Herrington, 2013). GLP-1 (7–36) amide intraportal infusion (0.9, 5.1, 10, 20 pmol.kg^-1.min^-1) increased glucose uptake (hepatic and peripheral) and the glucose infusion rate necessary to maintain blood glucose levels (Nishizawa et al., 2003). In hyperglycemic clamp, dogs treated with of GLP-1 (32–36) amide cleavage-derived pentapeptide (30 pmol.kg^-1.min^-1) increased glucose uptake regardless of insulin and glucagon changes (Elahi et al., 2014). Taken together, these studies reinforce the hypothesis that unlike rodents and humans, in dogs, the main action of GLP-1 is to stimulate glucose uptake instead of insulin release, although this action still needs to be better understood, especially the molecular mechanisms involved. Initially, this may be a promising finding, after all, GLP-1 action would be less dependent on β cells, which are highly damaged in canine DM (Gilor et al., 2016). However, unlike what occurs in feline DM, insulin resistance in dogs is not a primary factor in DM development (Gilor et al., 2016). Thus, it is possible to speculate what is the real benefit of this treatment for diabetic dogs. Besides, there are still many aspects to be explored until its applicability could be encouraged or dropped.

Although numerous molecules related to GLP-1 actions are available, clinical studies focused on obesity or overweight treatment with this drugs in dogs are limited to pharmacokinetic (Jain et al., 2015, 2017; Yeh et al., 2021). Exenatide effects were evaluated in a pre-diabetes canine model (high-fat diet plus streptozotocin injection). The animals without treatment developed increased body weight, reduced glucose tolerance and higher fasting blood glucose, but insulin sensitivity was
Veterinary and Animal Science 16 (2022) 100245

7

cardiovascular diseases. In an ischemia-reperfusion model, the DPP4i canine obesity treatment (Gilor et al., 2016; Ionut et al., 2016) dogs, the results indicates that GLP-1As may become one alternative to model, prediabetes, reproduces a human condition of low occurrence in increased insulin secretion in vitro (Ionut et al., 2016). Although this weight loss, but did not affect food consumption, fasting glucose, insu-

not altered. Exenatide treatment (10 μg per dog BID for 12 weeks) led to weight loss, but did not affect food consumption, fasting glucose, insulin, glycated hemoglobin or OGTT. In the same study, exenatide increased insulin secretion in vitro (Ionut et al., 2016). Although this model, prediabetes, reproduces a human condition of low occurrence in dogs, the results indicates that GLP-1As may become one alternative to canine obesity treatment (Gilor et al., 2016; Ionut et al., 2016).

Another focus of investigations are the effects of GLP-1 on canine cardiovascular diseases. In an ischemia-reperfusion model, the DPP4i alogliptin (3 mg.kg⁻¹), suppressed apoptosis pathways in heart extracts (Ibara et al., 2015). In a model of rapid atrial pacing, lilaglutide treatment (150 μg.kg⁻¹) was able to decrease the refractory period and lead to increased conduction velocity after 2 or 3 weeks (Nakamura et al., 2019). Pretreatment with GLP-1 (7–36) amide (2.5 pmol.kg⁻¹.min⁻¹) in a model of dilated cardiomyopathy decreased FFA levels and improved cardiac insulin resistance. In addition, GLP-1 treatment in elderly dogs increased latency for heart disease development and reduced mortality (Chen, Angeli, Shen & Shannon, 2014). In dogs with induced cardiomyopathy, the metabolite GLP-1 (9–36) amide improved left ventricular function. GLP-1 (9–36) amide also improved glucose uptake and cardiac output, without modifying insulin levels, presenting an insulinomimetic effect without insulinoceptive action (Nikolaidis, Elahi, Shen & Shannon, 2005). Although there are still few studies and the knowledge on the subject is not sufficiently depth, the available data shows a potential beneficial effect of using GLP-1 mimetics in different models of cardiac insult.

5. Concerns and perspectives

The studies so far do not report serious side effects related to GLP-1As use, however, in high doses they can lead to gastrointestinal problems, such as nausea, vomiting and diarrhea (Hall et al., 2015; Moore et al., 2013). In humans, GLP-1As have already been related to an increase in neoplasms development, such as pancreatic adenocarcinoma and

| Table 2 |
| GLP-1-based drug studies in dogs. |

| Breed | Age (years) | Sex | Castration | Condition | Drug | Brant / Manufacturer | Dosage | Treatment Duration | Complications | Ref |
|-------|-------------|-----|------------|-----------|------|----------------------|--------|-------------------|--------------|-----|
| NI    | NI          | NI  | NI         | healthy   | vildagliptin | NI     | 1 mg. kg⁻¹           | acute       | NO            | (Edgerton et al., 2009) |
| Beagle| M           | NI  | NI         | healthy   | gemigliptin  | NI / LG Life Sciences | 1 mg. kg⁻¹ | acute   | NI           | (Iiom et al., 2015) |
| Beagle| 3 to 5      | F/ M| All        | healthy   | sitagliptin  | Januvia/ MSD K. K. | 1 mg. kg⁻¹ | 7 days   | NI           | (Oda et al., 2014) |
| Mongrel| NI         | F/ M| NI         | depencratureized | GLP-1 (7–36) amide | NI / Bachem | 1.5 pmol. kg⁻¹.min⁻¹ | acute       | NI | (Sandhu et al., 1999) |
| ASID-strain | 2.8 ± 0.4 | F/ M| NI         | DM        | GLP-1 (7–36) amide | NI / Saxon Biochemicals | 10 pmol. kg⁻¹.min⁻¹ | acute   | NI | (Freysie et al., 1999) |
| Beagle - MDH | 3 to 11 | F/ M| 6 (of 9) | DM – healthy | lilaglutide | Victoza/ Novo Nordisk | 15 μg. kg⁻¹ | acute | NI | (Oda et al., 2013) |
| Mongrel| NI         | F/ M| NI         | healthy   | lixisenatide | NI / Sanofi | 1.5 μg. kg⁻¹ | acute   | vomiting | (Moore et al., 2013) |
| Mongrel| 3.2 ± 0.7 | F/ M| NI         | healthy   | GLP-1 (32–36) amide | NI / Massachusetts General Hospital | 30 pmol. kg⁻¹.min⁻¹ | acute | NI | (Elahi et al., 2014) |
| Beagle| 3 to 4 | M | NI | 2 – 3 | healthy | ZY15557 | NI / Zyus Research center | 0.5 – 3 mg.kg⁻¹ | acute | NI | (Jain et al., 2017) |
| Beagle | adults | M | NI | 2 – 6 | healthy | ZYDPLA1 | NI / Zyus Research center | 0.5 – 2 mg.kg⁻¹ | acute | NI | (Jain et al., 2017) |
| Beagle | 7 to 8 | | | healthy | GLP-1 (7–36) amide | NI / Sigma Aldrich | 0.9 – 5.1 pmol. kg⁻¹ | 10 – 20 pmol. kg⁻¹.min⁻¹ | acute | NO | (Nishizawa et al., 2005) |
| Mongrel| 3.2 ± 0.7 | F/ M| NI | healthy | GLP1 (32–36) amide | NI / Massachusetts General Hospital | 30 pmol. kg⁻¹.min⁻¹ | acute | NI | (Elahi et al., 2014) |
| Beagle| 1 to 2 | M | NI | 7 | pre-DM model | exenatide | 10 μg³ | 12 weeks | NI | (Jonat et al., 2016) |
| Beagle | adults | F | NI | 6 | ischemia-reperfusion model | alogliptin | 3.3 mg. kg⁻¹ | 12 days | NI | (Ibara et al., 2015) |
| Beagle | 3 – 10 to 12 | NI | NI | 7 – 9 | cardiomyopathy | GLP – 1 (7–36) amide | 2.5 pmol. kg⁻¹.min⁻¹ | 7 weeks | NI | (Chen et al., 2014) |
| Mongrel| NI | F/ M| NI | 7 – 9 | cardiomyopathy | GLP – 1 (7–36) and (9–36) amide | 1.5 pmol. kg⁻¹.min⁻¹ for both | 48 h | NI | (Nikolaidis et al., 2005) |
| Beagle | adults | F | NI | 3 – 4 | cardiomyopathy | Victoza/ Novo Nordisk | 150 μg. kg⁻¹ | 24 days | NI | (Nakamura et al., 2019) |

NO: not observed. NI not informed. DM: diabetes mellitus. MDH: miniature Dachshund.

*the authors reported only the total administered.

**the animals were divided into groups according to age into young (3 years) and old (10 to 12 years).
thyroid C-cell tumor, but recent meta-analyses of randomized controlled trials failed to show any significant increase in cancer risk (Cao, Yang & Zhou, 2019; Monami et al., 2017; Vangoirsenhoven, Mathieu & Van der Schueren, 2012). Studies evaluating GLP-1A administration and the risk of tumor development in domestic animals are still lacking.

A possible risk of DPP4i treatments stems from the fact that DPP4 (also known as CD26) is a T cell stimulator, so theoretically its inhibition could disrupt immune system regulation (Anz et al., 2014; Ohnuma, Dang & Morimoto, 2008). However, there is essentially no evidence that DPP4i cause deficiencies in the immune response. (Anz et al., 2014). The possibility that DPP4i may be harmful to animals with immune deficiency still needs to be clarified.

Human studies also show that DPP4i could slightly increase pancreatitis risk (from 0.067 to 0.117), which may be of particular concern for dogs (Aziz et al., 2020; DeVries & Rosenstock, 2017). Although the primary cause of DM in dogs often remains unknown, it is possible that a large percentage is due to complications from pancreatitis that lead to β-cell damage (Gillor et al., 2016). Yet, some studies demonstrate that GLP-1R activation in β cells inhibits apoptosis enhancing these cells survival (Aziz et al., 2020; DeVries & Rosenstock, 2017; Li et al., 2003). Thus, understanding how drugs based on GLP-1 act in the pancreas of dogs, protecting β cells or facilitating the development of pancreatitis, is a fundamental step towards their inclusion in the treatment of canine DM.

Castration is another factor that needs to be better evaluated. Recent studies have shown that sex steroids, especially testosterone and estradiol, modulates GLP-1 response in different tissues (El Bekay et al., 2016; Handgraaf, Dusaulcy, Visentin, Philippe, Handgraaf, Dusaulcy, Visentin, Philippe, 2018; Maske, Jackson, Terrill, Eckel & Williams, 2017; Navarro et al., 2016). Although these are still initial data, there are indications that GLP-1 response of castrated males is lower than that of intact animals (El Bekay et al., 2016; Model et al., 2021b). On the other hand, castrated females would not only respond similarly to intact ones, but treatment with GLP-1As could reverse part of the metabolic problems associated with estrogens reduction (Handgraaf et al., 2018; Model et al., 2021a). Even though these data do not come from domestic animals, they indicate an important factor to be evaluated in future studies.

Currently, the body of evidence available in the literature indicates GLP-1As and DPP4-is as possible alternatives to DM treatment in domestic animals, but at present there is not enough information to recommend these drugs widespread clinical use. Many of the experiences described in this review have limitations that must be overcome. The experimental amostral number (N), usually between 2 and 5, must be increased to avoid erroneous inferences (Callegari-Jacques, 2003). Studies evaluating GLP-1A administration and the risk of tumor development in domestic animals are still lacking.

6. Conclusions

The data collected so far demonstrate that GLP-1 may have a species-specific action in dogs, being more insulinomimetic than insulinotropic, although the latter has already been observed. In cats, the physiological actions of GLP-1 seem like those considered classic in humans and rodents. In diabetic dogs, the use of drugs based on GLP-1 actions led to reduction in blood glucose and higher glucose uptake, while in diabetic cats there was a reduction in glycemic variability and in the need of exogenous insulin administration. Thus, available evidence indicates that GLP-1 based drugs could become alternatives to DM treatment in domestic animals. However, there are still many open points, and current data are surprisingly limited, not providing enough elements to recommend these drugs widespread clinical use.

Funding

This study was supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Pró-reitoria de Pesquisa (PRO-PESQ) of Universidade Federal do Rio Grande do Sul (UFRGS), Brazil.

Authors contributions

JFM: Writing - original draft, Visualization, Writing - review & editing. DSR: Writing - original draft. ACF: Data Curation. ASV: Visualization, Writing - Review & Editing.

Declaration of Competing Interest

None

References

Abd El Aziz, M., Cahyadi, O., Meier, J. J., Schmidt, W. E., & Nauck, M. A. (2020). Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: A meta-analysis based on cardiovascular outcomes trials. Diabetes, Obesity and Metabolism, 22(4), 699-704. 10.1111/dom.13924.

Anz, D., Kräger, S., Haubner, S., Rapp, M., Bourquain, C., & Endres, S. (2014). The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses. Diabetes, Obesity and Metabolism, 16(6), 569-572. 10.1111/dom.12246.

Appleton, D., Rand, J., & Sunvold, G. (2001). Insulin Sensitivity decreases with obesity, and lean cats with low insulin sensitivity are at greatest risk of glucose intolerance with weight gain. Journal of Feline Medicine and Surgery, 3(4), 211–228. 10.1053/jfms.2001.0138.

Baggio, I. L., & Drucker, D. J. (2002). Harnessing the therapeutic potential of glucagon-like peptide-1. Treatments in Endocrinology, 1(2), 117–125. 10.2165/00002677-200201020-00005.

Baggio, I. L., & Drucker, D. J. (2007). Biology of incretins: GLP-1 and GIP. Gastroenterology, 132(6), 2131–2157. https://doi.org/10.1053/j.gastro.2007.03.054.

Baggio, I. L., Ussher, J. R., McLean, B. A., Cao, X., Kabir, M. G., Mulvihill, E. E., et al. (2017). The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice. Molecular Metabolism, 6(11), 1339–1349. 10.1016/j.molmet.2017.08.010.

Ban, K., Noyan-Ashraf, H. M. H., Hoefer, J., Bolz, S. S., Drucker, D. J., & Husain, M. (2008). Cardioprotective and vasodilatory actions of glucagon-like peptide-1 receptor are mediated through both glucagon-like peptide-1 receptor-dependent and independent pathways. Circulation, 117(18), 2340–2350. 10.1161/CIRCULATIONAHA.107.739938.

Bierau, D., Imbemnon, M., Gallego, R., Senra, A., Herranz, D., Villarroya, F., et al. (2014). GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes, 63(10), 3346–3358, 10.2337/db14-0302.

Bullock, B. P., Heller, R. S., & Habener, J. F. (1996). Tissue distribution of messenger ribonuclease acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology, 137(7), 2968–2978. 10.1210/endo.137.7.8770921.

Büneumann, M., Gerhardtstein, B. G., Tao, G., & Hseye, M.M. (1999). Functional regulation of l-type calcium channels via protein kinase A-mediated phosphorylation of the β subunit. Journal of Biological Chemistry, 274(48), 33851–33854. 10.1074/jbc.274.48.33851.

Butaye, J. E., Ansaud, W., Rhodes, C. J., Rosenberg, L., Joly, E., & Prentki, M. (2004). Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia, 47(5), 806–815. 10.1007/s00125-004-1379-6.

Butaye, J. E., Foisy, S., Joly, E., & Prentki, M. (2003). Glucagon-like peptide-1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes, 52(1), 124–132, 10.2377/diabetes.52.1.124.

Callegari-Jacques, S.M. (2003). Bioestatistica: Princípios e aplicações. Porto Alegre: ARTMED.

Camara, A., Verbrugge, A., Cargo-Froom, C., Hogan, K., DeVries, T. J., Sanchez, A., et al. (2020). The daytime feeding frequency affects appetite-regulating hormones, amino acids, physical activity, and respiratory quotient, but not energy expenditure in adult cats fed regimens for 21 days. PloS one, 15(9), Article e0238522, 10.1371/journal.pone.0238522.

Cao, Y., Yang, S., & Zhou, Z. (2019). GLP-1 receptor agonists and risk of cancer in type 2 diabetes: An updated meta-analysis of randomized controlled trials. Endocrine, 62(02), 157–165, 10.1007/s12020-019-02055-z.

Challa, T. D., Beaton, N., Arnold, M., Rudofsky, G., Langhans, W., & Wolfram, C. (2012). Regulation of adipocyte formation by GLP-1/GLP-1R signaling. Journal of Biological Chemistry, 287(9), 6421–6430. 10.1074/jbc.M111.310342.
Tolhurst, G., Reimann, F., & Gribble, F. M. (2009). Nutritional regulation of glucagon-like peptide-1 secretion. *The Journal of Physiology, 587*(1), 27–32, 10.1113/jphysiol.2008.164012.

Tsunekawa, S., Yamamoto, N., Tsukamoto, K., Itoh, Y., Kaneko, Y., Kimura, T., et al. (2007). Protection of pancreatic β-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies. *Journal of Endocrinology, 193*(1), 65–74, 10.1677/JOE-06-0148.

Van Citters, G. W., Kabir, M., Kim, S. P., Mittelman, S. D., Dea, M. K., Brubaker, P. L., et al. (2002). Elevated glucagon-like peptide-1-(7–36)-amide, but not glucose, associated with hyperinsulinemic compensation for fat feeding. *The Journal of Clinical Endocrinology & Metabolism, 87*(11), 5191–5198, 10.1210/jc.2002-020002.

Vangoitsenhoven, R., Mathieu, C., & Van der Schueren, B. (2012). GLP1 and cancer: Friend or foe? *Endocrine-Related Cancer, 19*(5). F77–F88. 10.1530/ERC-12-0111.

Wang, Y., Egan, J. M., Raygada, M., Nadin, O., Roth, J., & Montrose-Rafizadeh, C. (1995). Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in BIN 1046–38 cells. *Endocrinology, 136*(11), 4910–4917, 10.1210/endo.136.11.7588224.

Wettergren, A., Wojdemann, M., Meisner, S., Stadil, F., & Holst, J. J. (1997). The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. *Gut, 40*(5), 597–601, 10.1136/gut.40.5.597.

Yeh, K.-C., Yeh, T.-K., Huang, C.-Y., Hu, C.-B., Wang, M.-H., Huang, Y.-W., et al. (2021). DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity. *Life Sciences, 278*, Article 119574. https://doi.org/10.1016/j.lfs.2021.119574